Skip to main content
Back
IBRX logo

ImmunityBio, Inc.

Data quality: 100%
IBRX
NASDAQ Healthcare Biotechnology
$9.40
▲ $0.93 (10.98%)
Mkt Cap: 9.66B
Day Range
$8.46 $9.54
52-Week Range
$1.83 $12.43
Volume
26,514,739
50D / 200D Avg
$7.10 / $3.63
Prev Close
$8.47

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E -27.5 0.4
P/B 2.9
ROE % 3.7
Net Margin % -310.2 3.8
Rev Growth 5Y % 231.9 10.0
D/E 0.2

Key Takeaways

Revenue grew 231.86% annually over 5 years — strong growth
Negative free cash flow of -308.78M
PEG of 0.15 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 436.45%
Capital efficient — spends only 3.39% of revenue on capex

Growth

Revenue Growth (5Y)
231.86%
Revenue (1Y)668.31%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
N/A
ROIC-50.73%
Net Margin-310.18%
Op. Margin-226.00%

Safety

Debt / Equity
N/A
Current Ratio5.10
Interest Coverage-2.28

Valuation

P/E Ratio
-27.50
P/B RatioN/A
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 668.31% Revenue Growth (3Y) 1249.57%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 231.86% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 113.29M Net Income (TTM) -351.40M
ROE N/A ROA -70.01%
Gross Margin 99.34% Operating Margin -226.00%
Net Margin -310.18% Free Cash Flow (TTM) -308.78M
ROIC -50.73% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 5.10
Interest Coverage -2.28 Dividend Yield 0.00%
Valuation
P/E Ratio -27.50 P/B Ratio N/A
P/S Ratio 85.31 PEG Ratio 0.15
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 9.66B Enterprise Value 10.45B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 113.29M 14.75M 622,000.0 240,000.0 934,000.0
Net Income -351.40M -413.56M -583.20M -416.57M -346.79M
EPS (Diluted) -0.38 -0.62 -1.15 -1.04 -0.89
Gross Profit 112.54M 14.75M 622,000.0 240,000.0 934,000.0
Operating Income -256.03M -344.18M -362.25M -351.30M -330.28M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 501.90M 382.93M 504.45M 362.36M 468.91M
Total Liabilities 1.00B 871.06M 1.09B 812.18M 712.82M
Shareholders' Equity -499.57M -489.10M -586.99M -447.33M -242.17M
Total Debt 878.12M 504.17M 726.72M 723.77M 645.66M
Cash & Equivalents 88.33M 143.43M 265.45M 104.64M 181.10M
Current Assets 314.88M 184.59M 294.08M 140.58M 334.35M
Current Liabilities 61.75M 54.94M 58.28M 500.86M 369.00M